Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...
A quadruplet regimen is now the preferred first-line treatment for multiple myeloma in both transplant-eligible and ...
Zacks.com on MSN16h
FDA Accepts GSK's BLA for Blenrep Combos in Multiple MyelomaThe FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...
GlobalData on MSN4d
Health Canada issues NOC to J&J’s CARVYKTI for multiple myelomaThe study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...
Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...
News Medical on MSN12d
Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stagesMultiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback